Biotech / Medical
NanoViricides - Nanobiotechnology
An SI Board Since August 2016
Posts SubjectMarks Bans Symbol
1006 12 2 NNVC
Emcee:  donpat Type:  Moderated


Milton Boniuk
Vivien Boniuk
Curtis Brandt
Eva Harris
Jennifer Moffat
Robert Webster
Elena Govorkova

Headquarters: Shelton, Connecticut, United States

Founded: 2000

Stock Price Today

Novel Nanoviricides® Highly Effective Against Varicella Zoster Virus in Cell Culture
Brian M. Friedrich1, V Arora1, V Bulbule2, V Chiniga2, A Datar2, R Giri2, N Holkar2, P Holkar2, P Koranne2, K Medovich2, A Onton2 , R Pandey2, M Rawal2, A Singh2, J Tatake1,2, RW Barton1, and AR Diwan1,2
1NanoViricides, Inc. 1 Controls Dr., Shelton, CT (;
2AllExcel, Inc. 135 Wood St., West Haven, CT

**OTHERS using this virus trapping tech:

GL Hendricks
Modulating Influenza and Heparin Binding Viruses' Pathogenesis with Extrinsic Receptor Decoy Liposomes - eScholarship@UMMS › viewcontent

by GL Hendricks · 2013 · Related articles
Jun. 28, 2013 · Heparin sulfate decoy liposomes inhibit respiratory syncytial virus and herpes simplex virus. Preface . ...... infectious titer by trapping budding virus onto infected cell surfaces. Non-neutralizing anti-NP.

**Liposomal Decoys Capture Influenza A Virus

Background: Better treatments are needed for combating influenza.

Results: LSTc-sialoside-bearing decoy liposomes competitively bind to influenza A virus, as assessed by hemagglutination inhibition, flow cytometry, and growth inhibition studies. Decoy liposomes co-localize with influenza virus, as assessed by confocal imaging.

Conclusion: LSTc-sialoside-bearing decoy liposomes are highly effective in capturing influenza virus.

Significance: Decoy liposomes may serve as an effective platform for presenting anti-pathogen receptors.

Influenza is a severe disease in humans and animals with few effective therapies available. All strains of influenza virus are prone to developing drug resistance due to the high mutation rate in the viral genome. A therapeutic agent that targets a highly conserved region of the virus could bypass resistance and also be effective against multiple strains of influenza. Influenza uses many individually weak ligand binding interactions for a high avidity multivalent attachment to sialic acid-bearing cells. Polymerized sialic acid analogs can form multivalent interactions with influenza but are not ideal therapeutics due to solubility and toxicity issues. We used liposomes as a novel means for delivery of the glycan sialylneolacto-N-tetraose c (LSTc). LSTc-bearing decoy liposomes form multivalent, polymer-like interactions with influenza virus. Decoy liposomes competitively bind influenza virus in hemagglutination inhibition assays and inhibit infection of target cells in a dose-dependent manner. Inhibition is specific for influenza virus, as inhibition of Sendai virus and respiratory syncytial virus is not observed. In contrast, monovalent LSTc does not bind influenza virus or inhibit infectivity. LSTc decoy liposomes prevent the spread of influenza virus during multiple rounds of replication in vitro and extend survival of mice challenged with a lethal dose of virus. LSTc decoy liposomes co-localize with fluorescently tagged influenza virus, whereas control liposomes do not. Considering the conservation of the hemagglutinin binding pocket and the ability of decoy liposomes to form high avidity interactions with influenza hemagglutinin, our decoy liposomes have potential as a new therapeutic agent against emerging influenza strains.

Gabriel L. Hendricks‡, Kim L. Weirich§, Karthik Viswanathan¶, Jing Li¶, Zachary H. Shriver¶, Joseph Ashour?, Hidde L. Ploegh?, Evelyn A. Kurt-Jones‡, Deborah K. Fygenson§, **, Robert W. Finberg‡, James C. Comolli‡‡,1 and Jennifer P. Wang‡,2From the ‡Department of Medicine, University of Massachusetts Medical School, Worcester, Massachusetts 01605,§Biomolecular Science and Engineering Program,**Department of Physics, University of California, Santa Barbara, California 93106,the ¶Department of Biological Engineering, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139,?Whitehead Institute for Biomedical Research, Cambridge, Massachusetts 02142, and‡‡Charles Stark Draper Laboratory, Department of Bioengineering, Cambridge, Massachusetts 02139 ?2 To whom correspondence should be addressed: Dept. Medicine, University of Massachusetts Medical School, 364 Plantation St., Worcester, MA 01605. Tel.: 508-856-8414; Fax: 508-856-6176;

**Broad-spectrum non-toxic antiviral nanoparticles with a virucidal inhibition mechanism

Valeria Cagno, Patrizia Andreozzi, Marco D’Alicarnasso, Paulo Jacob Silva, Marie Mueller, Marie Galloux, Ronan Le Goffic, Samuel T. Jones, Marta Vallino, Jan Hodek, Jan Weber, Soumyo Sen, Emma-Rose Janecek, Ahmet Bekdemir, Barbara Sanavio, Chiara Martinelli, Manuela Donalisio, Marie-Anne Rameix Welti, Jean-Francois Eleouet, Yanxiao Han, Laurent Kaiser, Lela Vukovic, Caroline Tapparel, Petr Král, Silke Krol, David Lembo & Francesco Stellacci

An international research team including Petr Kral, a UIC professor of chemistry, has developed innovative anti-viral nanoparticles with the ability to bind to a range of viruses such as respiratory syncytial virus, herpes simplex virus, Dengue and Lentiviruses, and human papillomavirus. In contrast to other broad-spectrum antivirals, which just restrict viruses from infecting cells, the nanoparticles developed by the team have the ability to destroy viruses.

Kral and his team, which comprised assistant professor of chemistry Lela Vukovic from the University of Texas at El Paso who was an author on the paper, endeavored to develop an innovative anti-viral nanoparticle based on HSPG, yet one that will get attached more tightly to viral particles and kill them simultaneously.

A Swiss National Science Foundation NRP 64 grant, the National Centers of Competence in Research on Bio-Inspired Materials, the University of Turin, the Ministry of Education, Youth and Sports of the Czech Republic, the Leenards Foundation, National Science Foundation award DMR-1506886, and funding from the University of Texas at El Paso supported the study.
There are only two companies bringing this ligand virus binding technology to market; ExThera in a blood filtering system; NanoViricides in a drug, be it by mouth, injection or topical application. Both are following the FDA path to approval.
U.S. Food and Drug Administration (FDA) has granted ExThera’s Seraph® 100 Blood Filter (Seraph) the agency’s Expedited Access Pathway (EAP)

Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromPosted
1006msn.comSavant5 hours ago
1005An interesting use of nanoparticles in the wine industry: Posted: Jun 13, 2018donpatJune 14
1004Immitation/hegemony - ask yourself this - why are these researchers following NNdonpatJune 11
1003 From: donpat 6/11/2018 11:39:02 AM Read Replies (1) of 805 Yahoo! knows: UbdonpatJune 11
1001Date PostedBoardMessageReasonStatus 06/03/2018 08:05:25 PM NanoViricides Inc. FadonpatJune 8
1000Who wants the 1000th? I guess I do.donpatJune 6
999Cides are better! Ultrasound-powered nanorobots travel through blood to kill todonpatJune 6
998This lady looks to me like a fine addition to the NNVC attack force! Now to getdonpatJune 5
997Elena Govorkova, St. Jude Children's Research Hospital, USA [graphic] NandonpatJune 5
996What do I demand? Only one thing from HQ: Just a touch of enthusiasm; without donpatJune 4
995 Please refer to User Handbook - Deletion of Posts and the FAQ for more informdonpatJune 4
994BLOCKCHAIN FOR DUMMIES [graphic] Applying blockchain across industries and prodonpatJune 3
993 It's worth repeating, and I will do so frequently so we all know it and edonpatJune 2
992 [graphic] Zardiw[graphic] Saturday, June 2, 2018 9:11:01 AM Trying to get mordonpatJune 2
991 Just for the record: FAGIOperation I Balls I know I am, and I'm positive donpatJune 2
990I saw "Bullish" and read "Bullshit"! Just goes to show how donpatMay 30
989Bullish crossover in MACD and Stochastic oscillator. Might be the start of upsidAlejandroo GreenMay 30
988007 and viral infection: Study uncovers unconventional killer T cells capable odonpatMay 29
987msn.comSavantMay 28
986Discovery and Development of Penicillin The discovery and development of penicildonpatMay 24
985Doc Seymour - that ole geriatric genius!! Chembio Diagnostics, Inc. (CEMI) NasddonpatMay 24
984To: SI Ron (Soup Nazi) 5/23/2018 12:54:27 PM From: donpat Is it possible to knodonpatMay 23
983Antiviral Drugs Market to Reach US$82.9 Bn by 2024: Rising Prevalence of HIV/AIDdonpatMay 23
982Quantum Dots Light the Way for New Ebola and HIV Treatment March 15, 2016 GlobadonpatMay 23
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
Copyright © 1995-2018 Knight Sac Media. All rights reserved.Stock quotes are delayed at least 15 minutes - See Terms of Use.